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Abstract
Clear cell sarcoma of soft tissue (CCSST) represents a
highly malignant tumor of the musculoskeletal system
that is characterized by the chromosomal translocation
t(12;22)(q13;q12) of the Ewing sarcoma gene (EWSR1)
and activating transcription factor 1 (ATF1). In a former
microarray expression study, we identified ERBB3, a
member of the epidermal growth factor receptor (EGFR)
family, as a promising new diagnostic marker in the
differential diagnosis of CCSST. Here we show that,
besides ErbB3, all CCSST cell lines (n = 8) also express
the ErbB2 receptor or the ErbB4 receptor, representing
an adequate coreceptor of ErbB3. The phosphorylation
status of ErbB3 revealed these receptor pairs to be
either constitutively activated in CCSST cells with high
neuregulin-1 (NRG1) expression (n = 4) or activatable by
exogenic NRG1 in cells showing low amounts of NRG1
mRNA (n = 4). Exogenous NRG1 stimulated the growth
of a subset of CCSST cells but did not affect the kinetics
of another subset. This difference was not strictly de-
pendent on endogenous NRG1 expression; however,
the growth-inhibiting effect of the pan-ErbB tyrosine
kinase inhibitor CI-1033 or PD158780 clearly correlated
with NRG1 expression indicating an autocrine growth
stimulation loop, which may constitute an interesting
target of new therapeutic strategies in this tumor entity.
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Introduction
Clear cell sarcoma of soft tissue (CCSST) is a rare malig-
nancy of the musculoskeletal system that mainly affects
adolescents and young adults [1]. Because this entity usu-
ally shows a characteristic melanocytic differentiation and
is commonly associated with tendons and aponeuroses, the
tumor is also termed malignant melanoma of soft parts [2].
Tumor cells are characterized by the presence of a balanced
t(12;22)(q13;q12) translocation: the result is a fusion between
the Ewing sarcoma gene (EWSR1) and the activating transcrip-
tion factor 1 (ATF1) gene, which permits the expression of an
EWS–ATF1 oncoprotein [3].
The resistance of this tumor entity to chemotherapeutic
drugs that are effective in other soft tissue tumors constitutes
the major problem in the treatment of CCSST [4,5]. To charac-
terize this tumor at the molecular level and to screen for new
therapeutic options, Schaefer et al. [6] and Segal et al. [7]
examined CCSST by expression profile analysis. Both primary
tumor tissues from CCSST patients and cell lines derived
from these tumors could be shown to constitutively overexpress
ERBB3 (v-erb-B2 erythroblastic leukemia viral oncogene ho-
molog 3), which belongs to the epidermal growth factor receptor
(EGFR) tyrosine kinase family.
The human EGFR family of receptor tyrosine kinases con-
trols critical pathways involved in the differentiation, growth,
division, and motility of normal epithelial cells (reviewed in
Casalini et al. [8]). Moreover, in many types of cancer, the
process of malignant transformation and progression involves
an uncontrolled activation of these receptors and their cor-
responding ligands [9].
Among this family of membrane-bound tyrosine kinase re-
ceptors, which, in general, can act either as homodimers or
as heterodimers, ErbB2 and ErbB3 each plays an outstanding
Address all correspondence to: Christopher Poremba, MD, PhD, Institute of Pathology,
Heinrich-Heine-University, Moorenstr. 5, 40225 Du¨sseldorf, Germany.
E-mail: poremba@med.uni-duesseldorf.de
1This work was supported by grants from the ‘‘Elterninitiative Kinderkrebsklinik eV
Duesseldorf,’’ the ‘‘Forschungskommission der Medizinischen Fakulta¨t Du¨sseldorf,’’ and
EuroBoNet (6th Framework Network of Excellence of the European Union).
2Karl-Ludwig Schaefer and Kristin Brachwitz contributed equally to this study.
Received 17 March 2006; Revised 24 May 2006; Accepted 26 May 2006.
Copyright D 2006 Neoplasia Press, Inc. All rights reserved 1522-8002/06/$25.00
DOI 10.1593/neo.06238
Neoplasia . Vol. 8, No. 7, July 2006, pp. 613 –622 613
www.neoplasia.com
RESEARCH ARTICLE
role because no natural ligand has yet been identified
for ErbB2 and because ErbB3 has lost its tyrosine kinase
activity (reviewed in Citri et al. [10]). Hence, in nontrans-
formed tissue, both receptors are active only in the context of
ErbB heterodimers.
The most prominent ligand of ErbB3, neuregulin-1, shows
a high diversity of different isoforms resulting from three
different promoters/start exons (NRG1 types I, II, and III), in
combination with different C-terminal ends of the coding
sequence and, in addition, a broad spectrum of alternative
splicing. In the past, this diversity has led to some inconsis-
tency in the literature that is related to the use of synonyms
(type I: neu differentiation factor, NDF; heregulin, HRG;
acetylcholine receptor– inducing activity, ARIA; type II: glial
growth factor, GGF; type III: sensory- and motor neuron-
derived factor, SMDF) [11].
The NRG1/ERBB signaling axis has earned increased
attention in cancer research because of the development of
antibodies and small-molecule tyrosine kinase inhibitors that
specifically target components of the HER–kinase axis for
cancer therapy [12].
Therefore, the aim of this study is to systematically eval-
uate the impact of the neuregulin/ERBB signaling pathway on
the growth behavior of CCSST and to obtain hints for the
underlying mechanism of ERBB3 activation.
Materials and Methods
Tumor Cell Lines/Clinical Samples
Our experiments included 20 cell lines derived from typical
solid (pediatric) tumors and three breast carcinomas listed
in Table 1. All cell lines were maintained using standard
procedures, as previously described [13]. The absence of
Mycoplasma contamination was determined by the polymer-
ase chain reaction (PCR)–based VenorGeM Mycoplasma
PCR Detection Kit (Minerva Biolabs GmbH, Berlin, Ger-
many), according to the manufacturer’s protocols.
In addition to three cryopreserved tumor biopsies from
CCSST patients, which we received for diagnostic purposes,
three Ewing tumors (ET) [kindly provided by A. Kulozik
(Heidelberg, Germany); M. Weiss (Cologne, Germany);
and S. Burdach (Halle-Wittenberg, Germany)], two neuro-
blastomas (NB; U. Goebel, Du¨sseldorf, Germany), and one
osteosarcoma (OS; R. Krauspe, Du¨sseldorf, Germany) were
available for protein analysis.
Comparative Genomic Hybridization (CGH)
of Tumor Cell Lines
To determine whether ERBB3 gene activation is related
to DNA amplification, we performed chromosomal high-
resolution (HR) CGH. In HR-CGH, CGH profiles obtained
with standard experimental procedures [14] are evaluated
with a specific algorithm that employs dynamic standard
reference intervals instead of fixed thresholds [15]. This ap-
proach results in a three-fold increase in sensitivity compared
to standard chromosomal CGH [16].
CGH was performed as described previously [17]. Briefly,
sample DNA and normal male reference DNA (2 mg each)
were directly labeled with Spectrum Green and Spectrum
Red dUTP (Vysis, Downers Grove, IL), using nick translation.
The amounts of DNase and DNA Polymerase (Invitrogen,
Karlsruhe, Germany) and the reaction time were carefully
adjusted to obtain labeled DNA fragment lengths of 500 to
2000 bp on a 1% agarose gel. Approximately 800 ng of
labeled DNA and 20 mg of Cot1 DNA (Invitrogen) were hy-
bridized to normal metaphase chromosomes (Vysis). Slides
were hybridized for 3 to 4 days, washed, and counterstained
with 4,6-diamidino-2-phenylindole (Sigma, Mu¨nchen, Ger-
many). CGH image capture was performed with a charge-
coupled device camera on a Zeiss Axioscope epifluorescence
microscope (Zeiss, Jena, Germany) using dedicated Cyto-
vision software and hardware for HR-CGH (Applied Imaging
Corporation, Santa Clara, CA). In each case, 15 metaphases
were analyzed. After background fluorescence subtraction,
the green/red ratio of each entire metaphase was normalized
to 1.0. Average fluorescence ratios and 95% confidence
intervals were calculated from at least 12 representative
chromosomes and compared to dynamic standard reference
intervals. Chromosomal regions were considered unbalanced
if the 95% confidence intervals of tumor DNA hybridization did
not overlap with dynamic standard reference intervals, thus
being comparable to a statistical significance of P < .05.
Quantitative Reverse Transcription PCR (qRT-PCR)
for NRG1
Total RNA was isolated with TRI reagent (Sigma, Tauf-
kirchen, Germany), according to the manufacturer’s protocol.
To avoid contamination fromgenomicDNA,RNAwasdigested
with RNase-free DNase (Promega, Mannheim, Germany).
One microgram of total RNA was used for synthesizing
cDNA with First Strand synthesis kit (Amersham, Freiburg,
Germany).
Table 1. Characterization of Tumor Cell Lines.
Name Diagnosis Source
STA-ET-1 ET P. F. Ambros (Vienna, Austria)
RM-82 ET F. van Valen (Muenster, Germany)
TC-71 ET T. J. Triche (Los Angeles, CA)
SK-N-Mc ET ATCC-LGC (Promochem, London, UK)
WE-68 ET F. van Valen
DTC1 CCSST K. A. Lee (Hong Kong, China)
GG-62 CCSST F. van Valen
KAO CCSST K. A. Lee
MA-OH1 CCSST S. Stegmaier (Stuttgart, Germany)
MST-1 CCSST S. K. Liao (Taoyuan, Taiwan)
MST-2 CCSST S. K. Liao
MST-3 CCSST S. K. Liao
Su-CCS1 CCSST K. A. Lee
IMR-5 NB A. Voigt (Jena, Germany)
KCN NB C. P. Reynolds (Los Angeles, CA)
SHEP-SF NB A. Eggert (Essen, Germany)
SK-N-SH NB ATCC
OST OS F. van Valen
SAOS-2 OS ATCC
SJSA-1 OS ATCC
BT-474 BrCa G. V. Minckwitz (Frankfurt, Germany)
MCF-7 BrCa F. van Valen
SK-BR-3 BrCa B. Brandt (Muenster, Germany)
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Levels of mRNA were determined by qRT-PCR using the
LightCycler system (Roche Diagnostics, Mannheim, Ger-
many) together with 2 SYBR Green Master Mix (Qiagen,
Hilden, Germany). Oligonucleotide primers used in this study
are listed in Table 2. For all primer pairs, an initial denatura-
tion/activation at 95jC for 15 minutes was followed by
45 cycles of denaturation at 95jC for 15 seconds, annealing
at 55jC for 25 seconds, and extension at 72jC for 20 seconds.
Quantitative analysiswas performed using the LightCycler
Software (version 3.5). The specificity of PCR products was
determined by the LightCycler Software’s melting curve
analysis. All quantitative measurements were performed as
two independent replica.
Detection of Neuregulin-1 Variants
The sequences of the oligonucleotide primers used in
RT-PCR are specified in Table 3. For the distinction of the
different variants of neuregulin-1, a set of six primer combi-
nations was employed, as listed in Table 4. This table also
includes the expected RT-PCR product sizes.
After an initial denaturation step, PCR amplification was
performed with 35 cycles under the following conditions:
denaturation at 94jC for 30 seconds, annealing at 55jC for
45 seconds, and extension at 72jC for 90 seconds. PCR
products were analyzed on 12% polyacrylamide gel by silver
stain detection.
Determination of Allele-Specific Gene Expression
For polymorphism analysis of the SILV gene on chromo-
some 12q13, genomic DNA and the corresponding RNA
transcripts were amplified by PCR andRT-PCR, respectively,
using the primers 5V-GAGGGAACAAGCACTTCCTG-3V
(sense) and 5V-GGCACCTTCTCAGGTGTCAT-3V (anti-
sense). Cycle sequencing was performed with the BigDye
Terminator system (PE Biosystems, Weiterstadt, Germany)
using SILV-re primer, and reaction products were analyzed
on an ABI PRISM 3700 sequencer (PE Biosystems). The RT-
PCR of SILV RNA using heat-inactivated reverse transcrip-
tase was included as negative control to prove the absence of
genomic DNA.
Western Blot Analysis
For the isolation of proteins from cells or tissues, standard
RIPA buffer was applied [50 mM Tris/HCl pH 7.4, 150 mM
NaCl, 1% Nonidet P-40, 0.5% Na-deoxycholate, and 0.1%
sodium dodecyl sulfate (SDS)] supplemented with NaF,
NaVO4, and Complete mini (Roche Diagnostics). Proteins
were separated on 7% SDS polyacrylamide gel electropho-
resis (PAGE) or 4% to 20% PAGEr Duramide Precast Gels
(Cambrex, Rockland, ME) and transferred onto prewetted
Protran 0.2-mm nitrocellulose membranes (Schleicher and
Schuell, Dassel, Germany). Benchmark prestained protein
ladder (Invitrogen) was used for size estimation.
ErbB3 protein was detected by the ErbB3 (C-17) antibody
(rabbit polyclonal IgG; Santa Cruz Biotechnology, Heidel-
berg, Germany), ErbB4 protein was detected by the HER4/
ErbB4 (111B2) rabbit monoclonal antibody (New England
Biolabs GmbH, Frankfurt, Germany), and ErbB2 oncoprotein
was detected by the c-erb-B2 antibody (rabbit polyclonal IgG;
DAKO, Glostrup, Denmark). Detection of protein tyrosine
phosphorylation was performed with anti–phosphotyrosine
clone 4G10 (mouse monoclonal IgG; upstate/Biomol, Ham-
burg, Germany). To ensure that equal amounts of proteins
were loaded, detection ofa-tubulinwith anti–a-tubulinwas in-
cluded in each experiment (mouse monoclonal IgG; Sigma).
Goat anti-rabbit IgG (Pierce, Rockford, IL) and goat anti-
mouse IgG (Pierce) peroxidase-conjugated secondary anti-
bodies were applied.
Whole cell lysate from the breast cancer cell line SK-BR-3
(Santa Cruz Biotechnology) was used as a positive control for
ErbB2 detection. TheRIPA lysate from the EGF-treated A431
human epithelial carcinoma cell line (upstate/Biomol) was
applied as a control for the analysis of anti-phosphotyrosine.
Neuregulin Stimulation
For growth factor stimulation, 5  105 cells/well were
seeded in six-well plates and incubated at 37jC until 70%
to 80% confluence had been achieved. For serum starvation,
cells were kept without or with 0.5% fetal calf serum (FCS) for
an additional 24 hours. Treatment with rhHRGb1 (R&D Sys-
tems, Minneapolis, MN) was performed for 10 minutes at
room temperature.
Inhibition of ErbB Signaling Pathway by Tyrosine
Kinase Inhibitors
To analyze the effects of ErbB signaling inhibition, 5 105
cells/well were seeded in six-well plates and incubated at
Table 2. Oligonucleotide Primers Used for qRT-PCR.
Primer RefSeq/5V Position DNA Sequence (5V–3V)
NRG1-EGF-fw NM_013962/1314 TACATCCACCACTGGGACAA
NRG1-EGF-rv NM_013962/1426 ATCTCGAGGGGTTTGAAAGG
Table 3. Oligonucleotide Primers Used for RT-PCR.
Gene RefSeq/5V Position DNA Sequence (5V–3V)
Type II-fw NM_013962/964 AACCTCAAGAAGGAGGTCAGC
Type I-fw NM_004495/459 CAAAGAAGGCAGAGGCAAAG
Type IIIF-fw NM_013959/1113 TCAGCAACTCAGCCACAAAC
c-rv NM_ 004495/1184 TGATGCAACAAAATTGGAAAA
3-rv NM_013962/1562 CAACAAGAAAGCAGCACCAA
a-rv NM_013960/1579 GCTTGGCGTGTGGAAATCTA
Table 4. Combination of Oligonucleotide Primers for the Determination of
Neuregulin-1 Variants and Characterization of Products.
Variant Sense Primer Antisense Primer Product Size (bp)
Type II b3 Type II-fw b3-rv 599
Type I (a, b1, b2) Type I-fw a-rv 1318–1460
Type I b3 Type I-fw b3-rv 748
Type I g Type I-fw g-rv 727
Type III (a, b1) Type III-fw a-rv 766, 781
Type III b3 Type III-fw b3-rv 311
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37jCuntil 70% to 80%confluence had been achieved. Added
were 5 and 20 mM CI-1033 [Pfizer, New York, NY; stock
solution in dimethyl sulfoxide (DMSO)] or 0.6 and 3 mM PD
158780 (Calbiochem, Schwalbach, Germany; stock solution
in DMSO). The controls contained DMSO only. After 6 hours
of incubation with inhibitors/DMSO at 37jC, 5 nM rhHRGb1
(see above) was applied for 10 minutes at room tempera-
ture in a subset of experiments for the determination of the
effect of blocked exogenous stimulation.
Growth Kinetics
For the determination of growth kinetics, cells were in-
oculated into 96-well plates in 100 ml of medium containing
10% FCS at cell densities ranging from 5000 to 20,000 cells/
well, depending on the cell doubling time. The plates were
incubated for 24 hours to allow cells to attach. By medium
exchange, FCS concentration was lowered to 0.5%, and
rhHRGb1 was added once as a single-spike dose to obtain
final concentrations from 0.05 to 50 nM. The plates were
incubated for an additional 8 to 96 hours at 37jC without any
change of medium. Four hours before the end of incubation,
20 ml of 3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium-
bromid (MTT) solution (5 mg/ml MTT in phosphate-buffered
saline) was added to each well. The medium was removed,
and 200 ml of DMSO was added to each well to redissolve
the dye. Absorbance at 570 nm was measured. All values for
growth stimulation or inhibition (see below) were calculated
as the mean of six replica.
Cytotoxicity Assay
The growth-inhibiting activity of tyrosine kinase inhibitors
was tested by standard MTT assay, as described above.
Inhibitor concentrations were applied within a range from
0.002 to 20 mM for CI-1033 (stock concentration of 8.0 mM
in DMSO) and from 0.003 to 3.0 mM for PD 158780 (stock
concentration of 1.2 mM in DMSO).
IC50 values were calculated as the concentration of tyro-
sine kinase inhibitor that reduces cell viability by 50% after
48 hours.
Statistical Analysis
Significance analysis by chi-square test was performed
using Microsoft EXCEL (Microsoft, Redmond, WA).
Results
ErbB Expression in CCSST
Eight CCSST cell lines were analyzed for ERBB3 protein
abundance in comparison to OS, NB, ET, and breast carci-
noma (BrCa) cell lines. All CCSSTsamples displayed a high
expression of the ErbB3 receptor (Figure 1A). A lower ex-
pression of this receptor is also detectable in the three BrCa
cell lines (BT-474, MCF7, and SK-BR-3), whereas moder-
ate ErbB3 expression was detectable in only 1 (OST) of 10
other pediatric tumor cell lines. In addition, we detected
the accumulation of ErbB3 in three translocation-positive
CCSST tumor biopsies (Figure 1B), indicating that the over-
expression of the ErbB3 receptor is a characteristic feature
of this entity and is not related to cell culture conditions. No
expression of ErbB3 protein could be detected in oneOS, two
NB, and three ET primary tumor specimens (data not shown).
Because the tyrosine kinase–deficient ErbB3 receptor
requires a heterodimerization partner for active signaling,
we also tested our panel of CCSST cell lines for the expres-
sion of ErbB2. By Western blot analysis, all but one (MA-
OH1) samples showed expression of ErbB2—the favored
dimerization partner in this receptor family (Figure 2A). In
comparison to SK-BR-3, which is characterized by massive
ErbB2 gene amplification, the expression in CCSSTwas only
moderate. Although none of the CCSST cell lines showed
EGFR expression (Figure 2B), we found a strong signal
for ErbB4 in the cell lines, which was negative for ErbB2
Figure 1. Western blot analysis for ErbB3 receptor expression in (A) CCSST cell lines (CS) compared with BrCa, OS, NB, and ET. (B) Cryopreserved CCSST
biopsies with CCSST cell lines Su-CCS1 and GG-62 as positive controls.
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(Figure 2C), indicating that in all eight cell lines, a possible
dimerization partner for ErbB3 is present.
Neuregulin Expression in CCSST
To analyze whether autocrine stimulation through the
ErbB signaling pathway is possible in CCSST, we investi-
gated whether neuregulin-1, the most prominent ligand of
ErbB3, was also produced by these tumor cells.
qRT-PCR neuregulin-1 By real-time PCR, we observed a
broad spectrum of NRG1 gene activity in the eight analyzed
CCSST cell lines. GG-62, MST-1, MST-2, and MA-OH1
showed high expression of NRG1 compared to the mean of
all cell lines (Figure 3). The other fourCCSSTcell lines display
only marginal expression of ligand mRNA.
In summary, 4 of 8 CCSST but only 2 of 14 of the control
panel of tumor cell lines expressed NRG1 above the average
of our cell line panel. Even if this does not reach the signifi-
cance level (P = .0704, chi-square test), it underlines the
increased impact of the NRG1/ErbB signaling pathway in
CCSST. Interestingly, in breast cancer cell lines, which are
also characterized by ErbB receptor expression such as in
CCSST samples, no amount or only minimal amounts of
NRG1 mRNA could be detected.
Determination of neuregulin-1 isoforms To identify at least
the most common transcript variants ofNRG1, we developed
a combination of RT-PCR assays to distinguish between
types I, II, and III (HRG, GGF, and SMDF, respectively).
RT-PCR data are summarized in Table 5. All CCSST cell
lines, except Su-CCS1, expressed a and/or b type I variants
and, to some extent, type II variants. In agreement with qRT-
PCR data (Figure 3), those cell lines with high overall expres-
sion of NRG1 also exhibited a strong PCR product intensity
of NRG1 variants. The expression pattern of NRG1 variants
in CCSST appears most similar to OS samples, keeping in
mind that the overall expression level in CCSST was no-
tably higher. ETcell lines differed from CCSST mainly by the
additional expression of the g type I variant. Expression of
type III (SMDF) was found exclusively in NB (four of four
NB; only weak signal in TC-71), making this entity fundamen-
tally different from sarcoma samples.
The BrCa cell lines did not express any NRG1 variants, as
expected, from the low level of NRG1 expression in qRT-
PCR (Figure 3).
Figure 2. Western blot analysis for (A) ErbB2, (B) EGFR, and (C) ErbB4
expression in CCSST. Positive controls for ErbB2: SK-BR-3 BrCa cells with
ERBB2 gene amplification; positive controls for EGFR: the A431 human epi-
thelial carcinoma cell line; positive controls for ErbB4: the BrCa cell line MCF7.
Loading controls were performed by staining for a-tubulin or -actin.
Figure 3. Real-time qRT-PCR to determine the relative expression of neuregulin-1 in CCSST, BrCa, OS, ET, and NB. For statistical calculation, expression values
were categorized as higher or lower than the average. Error bars indicate the SD of independent replica (n = 2). The cell line showing the highest expression (GG-
62) was assigned to 100%.
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Mechanism of Elevated ERBB3/NRG1 Expression
To determine whether gross genetic alterations may be
responsible for the recurrently elevated expression ofERBB3
at chromosome 12q13, CGH was used to detect genomic
imbalances in CCSST cell lines. In total, 59 partial chromo-
somal gains (mean = 7.4; range = 2–11) and 46 losses
(mean = 5.8; range = 1–8) were detected in the eight cell
lines. The most frequent gains were found at chromosomes
8q (8 of 8), 17q (6 of 8), 7q (6 of 8), 7p (5 of 8), and 8p (4 of 8).
Gains of chromosome 12q (ERBB3) were only detected in
GG-62 and MST1.
For NRG1, we found that three of four cell lines showing
elevated NRG1 mRNA levels were also characterized by
8p gains even if this did not achieve statistical significance
(P = .15, chi-square test). The most obvious losses were
found at chromosomes 9p (7 of 8) and 11q (7 of 8). All CGH
data are summarized in Table 6.
Because gains of chromosome 12q13 can obviously not
be the (sole) cause for the elevated ERBB3 expression in
CCSST, we sought for other possible geneticmechanisms for
gene activation. In a former study, we observed the chro-
mosome 12q13 region 5 Mb telomeric to the ATF1 break-
point to be a specific hotspot of gene activity in CCSST [6].
The genes ERBB3, CDK2, and SILV are all located in close
proximity to the activated 3V end of ATF1 and belong to the
group of the 54 most significantly upregulated genes in
CCSST, according to gene expression profiling analysis.
Because the SILV gene harbors a single-nucleotide poly-
morphism (dbSNP 1052165) within its exonic sequence, we
were able to discriminate between transcripts of this gene
from the normal and the rearranged chromosome 12. In none
of the three heterozygous CCSST cell lines (DTC1, GG-62,
and MST-2) could a difference in allele activity of the SILV
gene be observed (Figure 4), indicating that genes located on
Table 5. Expression Pattern of NRG1 mRNA Variants.
Cell Line Entity qRT-NRG1 Type II b3 Type I a, b1, b2 Type I b3 Type I g Type III a, b1, b2 Type III b3
DTC1 CCSST (+)   +   
GG-62 CCSST +++ + ++ ++   
KAO CCSST +  (+) +   
MA-OH1 CCSST +  + +   
MST-1 CCSST ++  ++ ++   
MST-2 CCSST +++ (+) ++ ++   
MST-3 CCSST + (+) ++ +   
Su-CCS1 CCSST +      
BT-474 BrCa (+)      
MCF7 BrCa       
SK-BR3 BrCa       
OST OS +  (+) +   
Saos OS (+)  ++    
SJSA1 OS (+)  ++ + (+)  
SKNMc ET +  ++ + (+)  
STA-ET1 ET ++  (+) + (+)  
TC-71 ET ++ + ++ ++ (+)  (+)
WE-68 ET ++  ++ + +  
IMR 5 NB (+)   (+)   +
KCN NB ++ +  +   +
SHEP-SF NB +  + + + + +
SKNSH NB + +  (+) (+) ++ +
RT-PCR products found for the respective NRG1 variants were classified [as +++, very strong; ++, strong; +, moderate; (+), weak; , not detectable] according to
the staining intensity of silver-stained acrylamide gels.
Table 6. Chromosomal Alterations Detected by CGH.
Cell Line Gains Losses
DTC1 3q, 7p q, 8p q, 17q 1p, 6q, 9p, 11p q, 14q,
15q, 19q
GG-62 5p q, 7p q, 8p q, 11p, 12p q,
17q 20q
1q, 6q, 9p q, 11q, 17p,
19p, 20p
KAO 1p q, 2p q, 5p, 6p, 7p q, 8q, 17q,
20q, 22q
11q
MA-OH1 6p, 7p q, 8q 1p, 3p, 9p, 11p q
MST-1 1q, 6p, 7p q, 8p q, 12q, 14q, 17q 6q, 9p q, 11p q, 15q, 16q
MST-2 1q, 4q, 5p, 7q, 8p q, 17q 9p, 17p, 19q, 20q
MST-3 8q, 16p 8p, 9p, 10p q, 11q
Su-CCS1 1p, 4q, 5q, 6q, 8q, 13q, 16p, 17q 1p, 9p, 10p, 11q, 16q,
17p, 19 p q
The gains of the loci of interest (8p/NRG1 and 12q ERBB3) are highlighted
in boldface.
Figure 4. Example of cycle sequence analysis of SILV genomic DNA and
RNA transcripts across a single-nucleotide polymorphism (arrow) to detect
imbalances in allelic expression. Heterozygous SILV alleles in the cell line
DTC1 were equally expressed.
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the rearranged chromosomal 12q arm are not generally
preferred to be transcribed at elevated levels.
ERBB3 Is Functionally Active in CCSST
Neuregulin stimulation (Western blot ERBB3/P-Tyr) To
further characterize the ErbB signaling pathway in CCSST,
we analyzed the phosphorylation status of theErbB3 receptor
before and after NRG1 ligand stimulation. The six cell lines
analyzed in the following series could clearly be divided into
two groups: those with high tyrosine phosphorylation even
in the absence of external neuregulin (GG-62 and MST-1;
example given in Figure 5B, data summarized in Table 7) and
those showing only marginal basal phosphorylation (MA-
OH1, KAO, and Su-CCS1 DTC1; example given in Figure 5,
A + C). Interestingly, the cell lines with high basal tyrosine
phosphorylation also harbored the most elevated levels of
NRG1 mRNA expression (Figure 3 and Table 7).
After neuregulin-1 stimulation, we observed a pronounced
increase of receptor phosphorylation in a dose-dependent
manner (50 pM–50 nM) in cell lines without high basal ErbB3
phosphorylation (representative example in Figure 5A),
whereas cells with high basal phosphorylation showed only
a moderate increase (MST-1) or even no increase in phos-
phorylation level (Figure 5B). In the cell line MA-OH1, which
was characterized by elevated ErbB4 expression instead of
ErbB2, only moderate receptor phosphorylation could be
induced. These data are summarized in Table 7.
Thephosphorylation signalwasalreadydetectable30sec-
onds after neuregulin application and persisted for at least
10 minutes in all stimulable cell lines (data not shown).
Activity of secreted heregulin To support the hypothesis that
the high basal tyrosine phosphorylation of ErbB3 is a conse-
quence of the expression and the release of the correspond-
ing ligand NRG1, we tested the conditioned medium of
GG-62 (high level of NRG1 mRNA and high basal phosphor-
ylation) for ErbB stimulation activity. As expected, the super-
natant of GG-62 induced ErbB3 phosphorylation in Su-CCS1
(low level of NRG1 mRNA and low basal phosphorylation)
comparable to 5 nM recombinant hHRGb1 (Figure 6).
Neuregulin stimulation (growth kinetics) To monitor the
impact of exogenous NRG1 stimulation on the growth be-
havior of CCSST, tumor cells were incubated in the presence
of 50 pM to 50 nM rhHRGb1, and growth kinetics was deter-
mined byMTTassay. In a subset of tumor cell lines, rhHRGb1
could be shown to promote cell growth in a time-dependent
and dose-dependent manner (see Figure 7 for representa-
tive examples).
We observed the tendency that CCSST cells expressing
higher levels of endogenous NRG1 could not further be
Figure 5. Western blot analysis to detect ERBB3 activation in (A) Su-CCS1
cells and (B) GG-62 cells stimulated with 0.05 to 50.0 nM rhHRG1 over
10 minutes. K: Control (10% FCS, no rhHRG1); /: low-serum Control
(0.5% FCS, no rhHRG1). (C) Only moderate receptor phosphorylation
can be induced in the ErbB3/ErbB4 positive cell line MA-OH-1.
Table 7. NRG1 mRNA Expression, ErbB Phosphorylation, and LD50 Values
of the CCSST Cell Line Treated with CI-1033 and PD158780.




GG-62 100.0 +++ +++ 0.12 0.9
DTC1 4.47 + +++ 3.5 > 3.0
KAO 7.57 + +++ 5.5 > 3.0
Su-CCS1 1.18 + +++ 10.0 > 3.0
MA-OH1 29.41 + ++ 3.5 > 3.0
MST-1 69.55 ++ +++ 0.03 0.5
ErbB phosphorylation was analyzed by Western blot analysis, and signal
intensity was scored as (+) weak, (++) moderate, and (+++) strong.
Figure 6. Western blot analysis to detect ERBB3 activation in Su-CCS1 cells
incubated with conditioned medium from GG-62 cells. Su-CCS1 cells were
treated with 10% FCS (lane 1), 5 nM rhHRG1 (lane 3), or conditionedmedium
from GG-62 cells (lane 4) for 10 minutes. ERBB3 activation by conditioned
medium was comparable to induction achieved by applying 5 nM rhHRG1 for
10 minutes (lane 3). After 24 hours (lane 5), ErbB3 phosphorylation decayed
to background levels.
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stimulated to promote cell growth (GG-62 and MA-OH1,
except MST1), whereas cells without elevated NRG1 levels
responded to exogenous heregulin by growth acceleration
(DTC1 and KAO, except Su-CCS1) (Figure 8).
No morphologic changes could be detected in any of the
cell lines during the 96-hour incubation with heregulin (data
not shown).
Inhibition of ErbB signaling pathway by tyrosine kinase
inhibitor The impact of neuregulin/ErbB signaling onCCSST
tumor cells was further investigated by suppressing receptor
phosphorylation with pan-ErbB tyrosine kinase inhibitors CI-
1033 and PD158780, which both interact with the ATP-binding
site of the EGFR family members.
ErbB3 phosphorylation was completely or almost com-
pletely lost after a 6-hour incubation with CI-1033 or
PD158780 in CCSST cells with high basal levels of ErbB3
phosphorylation due to autocrine stimulation [representative
example (MST1) given in Figure 9]. Moreover, after pre-
incubation with the inhibitors, activation of ErbB3 receptor by
exogenous neuregulin was substantially reduced if not com-
pletely abolished.
To get first hints if suppression of ErbB signaling in CCSST
represents a new therapeutic option, the influence of pan-
ErbB tyrosine kinase inhibitors on the growth kinetics of
tumor cells was tested in vitro.
We observed a broad spectrum of LD50(48 hours) values
among the six analyzedCCSSTcell lines, ranging from 25 nM
(MST-1) to 10 mM (Su-CCS1) (Table 7). Interestingly, CCSST
cells were characterized by an inverse correlation between
endogenous NRG1 expression and resistance to the inhibitor
CI-1033 (measured by LD50 values, Pearson correlation, r =
0.82). The same tendency was observed using the inhibitor
PD158780; however, due to an overall higher tolerance of
CCSSTcells to PD158780, no correlation was calculated.
Discussion
CCSST is an aggressive and rare soft tissue tumor that ap-
pears to be histogenetically related to melanoma, but its
clinical behavior resembles soft tissue sarcoma. Patients
presenting with unresectable tumors have a very poor prog-
nosis because aggressive multiagent chemotherapy ap-
peared to have no impact on outcome [4,5,18].
The analyses presented here aim to discover signaling
pathways, which are critical for the malignant growth of
CCSST and might therefore constitute potential targets for
new therapeutic strategies. Our studies are based on the
previous mRNA expression profiling analyses indicating that
the ErbB3 growth factor receptor is highly expressed in
CCSST [6,7,19].
Based on Western blot analysis, in this study, we also
found the receptor protein to be present in 100% of CCSST
samples (three frozen tumor tissues and eight tumor cell
Figure 8. Growth stimulation by 5 nM recombinant hHRG1 in a panel of six
CCSST cell lines. Cells were treated with 5 nM rhHRG1 (black columns; no-
heregulin control, white columns) for 4 days, and cell viability was measured
by MTT assay. Error bar, SD.
Figure 9. Western blot analysis to detect ErbB2/ErbB3 inhibition in MST-1
cells with autocrine ErbB2/ErbB3 stimulation and in DTC1 cells with
rhHRG1-induced ErbB2/ErbB3 stimulation. ErbB2/ErbB3 inhibition was
achieved by treating the cells with (A) 5 and 20 M CI-1033, or (B) 0.6 and
3 M PD158780. Endogenous ErbB3 activity is demonstrated in control lanes
(K), which indicate cells without either tyrosine kinase inhibitors (TKI) or
rhHRG1. Exogenous ErbB2/ErbB3 activation in the absence of TKI is shown
in lanes labeled /5 nM HRG.
Figure 7. Growth kinetics to determine the impact of exogenous NRG1 on the
growth of the CCSST cell line, KAO. Tumor cells were incubated in the
presence of 50 pM to 50 nM rhHRG1 up to 96 hours, and cell viability was
measured by MTT assay. Error bars, ± SD.
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lines), whereas almost all other sarcoma or neuroectodermal
tumors from the control panel were negative.
Because ErbB3 has lost its kinase activity during evolu-
tion, it requires a coreceptor with kinase activity, preferentially
ErbB2, to transmit ligand-binding signals [10,20]. As an
important functional prerequisite, we show that the CCSST
cell lines also express moderate levels of ErbB2 (or ErbB4 in
one cell line), which enables these tumors to act through this
powerful signaling pathway. Because a subset of CCSSTalso
expresses neuregulin-1, the data presented here suggest
that NRG/ErbB receptor signaling plays a significant role in
this tumor entity. Indeed, we could demonstrate that cell lines
synthesizing high levels of neuregulin-1 also show elevated
ErbB3 phosphorylation levels and that, for all CCSST cell
lines, ErbB receptors are phosphorylated after the addition
of exogenous neuregulin-1. In our proliferation assays, the
one-time addition of exogenous neuregulin stimulated three
of six analyzed cell lines toward enhanced growth kinetics.
Even if we did not test whether continuous stimulation would
lead to a more heightened growth spurt of cells, we can
conclude from these data that neuregulin/ErbB signaling is
functionally relevant in CCSST.
Because the tissue of origin of CCSST is still a matter of
debate, it remains to be determined whether the expression
of ERBB3 in these tumor cells represents a residual differen-
tiation of the transformed cell of origin or an acquired feature
that is related to malignant transformation or progression.
The first hypothesis of residual expression of the progen-
itor tissue is supported by our observation that obligatory
t(12;22)(q13;12) translocation is not directly related to the
characteristic activation of the gene cluster at 12q13 (includ-
ing ERBB3, SILV, and CDK2 [6]) and that the gene locus on
12q13 is not recurrently amplified in CCSST.
Although the coexpression of ERB2 and ERB3 is a rarely
reported event in other sarcoma entities [21], recent inves-
tigations on primary tumor tissues of neuronal supportive ori-
gin, such as astrocytic glioma or malignant peripheral nerve
sheath tumors [22,23], have identified an autocrine stimula-
tion loop involving ErbB2, ErbB3, and the ligand neuregulin-1
as characteristic features. However, because NRG/ErbB
signaling is well known to play a critical role in neuromuscular
development and functional maintenance, ErbB and neure-
gulin expression is more likely a residual differentiation of the
tumor tissues in these entities.
The understanding of the multiple processes that mod-
ulate EGFR-related receptor signal transduction, such as
heterodimerization, tyrosine kinase activity, and endocytosis,
in special cancer types has revealed new opportunities in the
development of modern anticancer therapeutics (reviewed in
Yarden [24]). Therefore, considering the poor sensitivity of
CCSST to standard sarcoma combination chemotherapy, we
regard the impact of the ErbB/neuregulin signaling pathway
on clinical management to be of high interest.
One of the first anticancer agents to specifically target
members of the ErbB receptor family is trastuzumab, a hu-
manizedmonoclonal antibody against ErbB2. Clinical studies
have demonstrated the effectiveness of this antibody in the
treatment of advanced breast cancer showing ErbB2 over-
expression. Stimulated by these experiences, the arsenal
of anti-ErbB agents, such as specific antibodies or small-
molecule kinase inhibitors, is continuously growing and being
evaluated in clinical trials. However, it remains difficult to pre-
dict the response to adjuvant anti-ErbB therapy in individual
patients because, by far, not every tumor expressing ErbB re-
ceptors may be affected by the corresponding inhibitor
[25,26]. This phenomenon may be related to different mech-
anisms leading to uncontrolled ErbB activation, including gene
amplification, gene mutation, or epigenetic factors. In addition,
it should be considered whether the activation is ligand-
dependent or not [27,28]. In CCSST, we were able to show
those tumors characterized by a high degree of autocrine/
paracrine stimulation through the ErbB/neuregulin pathway to
be the most promising candidates for anti-ErbB therapy.
In other sarcomas, the clinical impact of ErbB receptor gene
activation andeven the prevalence of overexpressionandgene
amplification are still a matter of debate. In Ewing’s tumors for
example, which are also characterized by an EWS gene
rearrangement (as in CCSST), in none of 16 primary tumors
(regardless of 17q gain) were we able to detect any ErbB2
expression by immunohistochemistry and fluorescence in situ
hybridization analysis [29]. These findings were also confirmed
by other studies [30,31]. Furthermore, in a more recent study
on 113 Ewing’s tumor samples, 16% was found to express
ErbB2, but only focal to diffuse cytoplasmic staining, without
concomitant membranous staining, was observed. In addition,
in vitro treatment using the anti–HER-2 antibody trastuzumab
failed to reduce cell growth in Ewing’s tumor cells [31].
In summary, we demonstrate a high biologic impact of
ErbB/neuregulin signaling at least in the subset of CCSST,
which is characterized by significant autocrine or paracrine
stimulation. Thus, our molecular genetic analysis consti-
tutes the basis of the further evaluation of anti-ErbB–based
therapeutic concepts in these otherwise chemotherapy-
resistant tumors.
References
[1] Sciot R and Speleman F (2002). Clear cell sarcoma of soft tissue. In
World Health Organisation Classification of Tumours. Pathology and
Genetics of Tumours of Soft Tissue and Bone. In CD Fletchers, KK
Unni, F Mertens (Eds). IARC Press, Lyon, pp. 211–212.
[2] Chung EB and Enzinger FM (1983). Malignant melanoma of soft parts.
A reassessment of clear cell sarcoma. Am J Surg Pathol 7, 405–413.
[3] Zucman J, Delattre O, Desmaze C, Epstein AL, Stenman G, Speleman
F, Fletchers CD, Aurias A, and Thomas G (1993). EWS and ATF-1 gene
fusion induced by t(12;22) translocation in malignant melanoma of soft
parts. Nat Genet 4, 341–345.
[4] Ferrari A, Casanova M, Bisogno G, Mattke A, Meazza C, Gandola L,
Sotti G, Cecchetto G, Harms D, Koscielniak E, et al. (2002). Clear cell
sarcoma of tendons and aponeuroses in pediatric patients: a report
from the Italian and German Soft Tissue Sarcoma Cooperative Group.
Cancer 94, 3269–3276.
[5] Finley JW, Hanypsiak B, McGrath B, Kraybill W, and Gibbs JF (2001).
Clear cell sarcoma: the Roswell Park experience. J Surg Oncol 77,
16–20.
[6] Schaefer KL, Brachwitz K, Wai DH, Braun Y, Diallo R, Korsching E,
Eisenacher M, Voss R, Van Valen F, Baer C, et al. (2004). Expression
profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines
reveals characteristic up-regulation of potential new marker genes in-
cluding ERBB3. Cancer Res 64, 3395–3405.
[7] Segal NH, Pavlidis P, Noble WS, Antonescu CR, Viale A, Wesley
UV, Busam K, Gallardo H, DeSantis D, Brennan MF, et al. (2003).
Neuregulin/ERBB3 in Clear Cell Sarcoma of Soft Tissue Schaefer et al. 621
Neoplasia . Vol. 8, No. 7, 2006
Classification of clear-cell sarcoma as a subtype of melanoma by ge-
nomic profiling. J Clin Oncol 21, 1775–1781.
[8] Casalini P, Iorio MV, Galmozzi E, and Menard S (2004). Role of HER
receptors family in development and differentiation. J Cell Physiol 200,
343–350.
[9] Hynes NE and Lane HA (2005). ERBB receptors and cancer: the com-
plexity of targeted inhibitors. Nat Rev Cancer 5, 341–354.
[10] Citri A, Skaria KB, and Yarden Y (2003). The deaf and the dumb: the
biology of ErbB-2 and ErbB-3. Exp Cell Res 284, 54–65.
[11] Falls DL (2003). Neuregulins and the neuromuscular system: 10 years
of answers and questions. J Neurocytol 32, 619–647.
[12] Gross ME, Shazer RL, and Agus DB (2004). Targeting the HER–kinase
axis in cancer. Semin Oncol 31, 9–20.
[13] Wai DH, Schaefer KL, Schramm A, Korsching E, Van Valen F, Ozaki T,
Boecker W, Schweigerer L, Dockhorn-Dworniczak B, and Poremba C
(2002). Expression analysis of pediatric solid tumor cell lines using
oligonucleotide microarrays. Int J Oncol 20, 441–451.
[14] Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman
F, and Pinkel D (1992). Comparative genomic hybridization for molecu-
lar cytogenetic analysis of solid tumors. Science 258, 818–821.
[15] Kirchhoff M, Gerdes T, Rose H, Maahr J, Ottesen AM, and Lundsteen C
(1998). Detection of chromosomal gains and losses in comparative
genomic hybridization analysis based on standard reference intervals.
Cytometry 31, 163–173.
[16] Kirchhoff M, Gerdes T, Maahr J, Rose H, Bentz M, Dohner H, and
Lundsteen C (1999). Deletions below 10 megabasepairs are detected
in comparative genomic hybridization by standard reference intervals.
Genes Chromosomes Cancer 25, 410–413.
[17] Schneider DT, Schuster AE, Fritsch MK, Calaminus G, Gobel U, Harms
D, Lauer S, Olson T, and Perlman EJ (2002). Genetic analysis of me-
diastinal nonseminomatous germ cell tumors in children and adoles-
cents. Genes Chromosomes Cancer 34, 115–125.
[18] Jacobs IA, Chang CK, Guzman G, and Salti GI (2004). Clear cell sar-
coma: an institutional review. Am Surg 70, 300–303.
[19] Schaefer KL, Wai DH, Poremba C, Korsching E, Van Valen F, Ozaki T,
Boecker W, and Dockhorn-Dworniczak B (2002). Characterization of
the malignant melanoma of soft-parts cell line GG-62 by expression
analysis using DNA microarrays. Virchows Arch 440, 476–484.
[20] Holbro T, Civenni G, and Hynes NE (2003). The ErbB receptors and
their role in cancer progression. Exp Cell Res 284, 99–110.
[21] Ricci C, Landuzzi L, Rossi I, De Giovanni C, Nicoletti G, Astolfi A, Pupa
S, Menard S, Scotlandi K, Nanni P, et al. (2000). Expression of HER/
erbB family of receptor tyrosine kinases and induction of differentiation
by glial growth factor 2 in human rhabdomyosarcoma cells. Int J Cancer
87, 29–36.
[22] Ritch PS, Carroll SL, and Sontheimer H (2005). Neuregulin-1 enhances
survival of human astrocytic glioma cells. Glia 51, 217–228.
[23] Stonecypher MS, Byer SJ, Grizzle WE, and Carroll SL (2005). Activa-
tion of the neuregulin-1/ErbB signaling pathway promotes the prolifer-
ation of neoplastic Schwann cells in human malignant peripheral nerve
sheath tumors. Oncogene 24, 5589–5605.
[24] Yarden Y (2001). The EGFR family and its ligands in human cancer.
Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37
(4), S3–S8.
[25] Campos S, Hamid O, Seiden MV, Oza A, Plante M, Potkul RK, Lenehan
PF, Kaldjian EP, Varterasian ML, Jordan C, et al. (2005). Multicenter,
randomized phase II trial of oral CI-1033 for previously treated ad-
vanced ovarian cancer. J Clin Oncol 23, 5597–5604.
[26] Pegram MD, Konecny G, and Slamon DJ (2000). The molecular and
cellular biology of HER2/neu gene amplification/overexpression and the
clinical development of herceptin (trastuzumab) therapy for breast
cancer. Cancer Treat Res 103, 57–75.
[27] Shelton JG, Steelman LS, Abrams SL, Bertrand FE, Franklin RA,
McMahon M, and McCubrey JA (2005). The epidermal growth factor
receptor gene family as a target for therapeutic intervention in numer-
ous cancers: what’s genetics got to do with it? Expert Opin Ther Targets
9, 1009–1030.
[28] Ozaki T, Schaefer KL, Wai D, Yokoyama R, Ahrens S, Diallo R,
Hasegawa T, Shimoda T, Hirohashi S, Kawai A, et al. (2002). Population-
based genetic alterations in Ewing’s tumors from Japanese and European
Caucasian patients. Ann Oncol 13, 1656–1664.
[29] George E, Niehans GA, Swanson PE, Strickler JG, and Singleton TP
(1992). Overexpression of the c-erb-B2 oncogene in sarcomas and
small round-cell tumors of childhood. An immunohistochemical inves-
tigation. Arch Pathol Lab Med 116, 1033–1035.
[30] Thomas DG, Giordano TJ, Sanders D, Biermann JS, and Baker L
(2002). Absence of HER2/neu gene expression in osteosarcoma and
skeletal Ewing’s sarcoma. Clin Cancer Res 8, 788–793.
[31] Scotlandi K, Manara MC, Hattinger CM, Benini S, Perdichizzi S, Pasello
M, Bacci G, Zanella L, Bertoni F, Picci P, et al. (2005). Prognostic and
therapeutic relevance of HER2 expression in osteosarcoma and
Ewing’s sarcoma. Eur J Cancer 41, 1349–1361.
622 Neuregulin/ERBB3 in Clear Cell Sarcoma of Soft Tissue Schaefer et al.
Neoplasia . Vol. 8, No. 7, 2006
